Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Motor Activity 6Skin Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Melanoma 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Carcinoma, Merkel Cell 1Breast Neoplasms 1

Interventions

Nivolumab 3Niacinamide 2HhAntag691 2urelumab 1pembrolizumab 1fludarabine phosphate 1fludarabine 1encorafenib 1cemiplimab 1binimetinib 1avelumab 1aldesleukin 1X-Rays 1Vitamin A 1Tranexamic Acid 1Sunscreening Agents 1Niacin 1Mohs Surgery 1Itraconazole 1Ipilimumab 1Interleukin-2 1Influenza Vaccines 1Indocyanine Green 1Immune Checkpoint Inhibitors 1Exercise 1Dimethyl Sulfoxide 1Cyclophosphamide 1Biopsy 1Ascorbic Acid 1Aminolevulinic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Skin Neoplasms × Exercise × Clear all
NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Active not recruiting
22 enrolled
Dermatologic

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡